tbuckley/cabot-search huggingface dataset:
Prognostic factors in patients with advanced renal carcinoma.
Authors: C. Muriel, E. Esteban, A. Astudillo, P. Martinez-Camblor, N. Corral, G. Crespo, J. Berros, P. J. Fonseca, M. Luque, A. J. Lacave
Journal: Journal of Clinical Oncology (2011)

391 Background: A retrospective cohort of 135 patients with advanced RCC treated with biological agents and/or cytokines (CK) was analysed between July 1996 and February 2010. Methods: The expression of several biomarkers by immunohistochemistry and 2 analytical variables: thrombocytosis and neutrophilia were analysed and were correlated with prognosis. Results: 67 patients were treated only with biological agents and 68 with CK (23 received also biological agents). The univariate statistical analysis showed that the enhanced expression of HIF-1alpha correlated with a poor prognosis in patients treated with sunitinib (PFS was 5.4 vs. 13.4 months in those with low expression, p=0.001). The overexpression of ACIX was associated to a better prognosis in patients that received biological agents (PFS was 18.3 vs. 5.2 months in those with decreased expression, p&lt;0.001; OS was 32.1 vs. 7.8 months, p&lt;0.001), including sunitinib (PFS was 16.8 vs. 5.5 months, p&lt;0.001), sorafenib (PFS was 8 vs 3.5 months, p&lt;0.001)) and CK (PFS was 6.3 vs. 2.7 months, p=0.003; OS was 32.9 vs. 5.9 months, p=0.001). Positive PTEN was related to a good prognosis in patients treated with sunitinib (PFS was 15.1 vs. 6.5 months, p=0.003) and CK (PFS was 7.5 vs. 3.8 months, p=0.037, OS was 13.7 vs 7.9 months, p=0.039). The increased expression of p21 was related to a poor prognosis in patients that received biological agents (PFS was 5.9 vs. 16.8 months with high expression, p=0.024), including sunitinib (PFS was 6.2 vs 18.9 months, p&lt;0.001), sorafenib (PFS was 4 vs 9 months, p=0.013) and CK (PFS was 3.9 vs. 7.5 months, p&lt;0.001). Thrombocytosis was related to a poor prognosis in patients treated with CK (PFS was 2.6 vs. 5.1 months p=0.017; OS was 5.9 vs. 14.3 months p=0.010). Neutrophilia was related to a poor prognosis in patients that received CK (PFS was 2.6 vs. 5.7 months, p=0.019; OS was 5.9 vs. 12.8 months, p=0.035). In the multivariate analysis, the overexpression of ACIX was a favorable prognostic factor independent of PFS with a HR of 0.107 (p&lt;0.001) and OS with a HR of 0.055 (p&lt;0.001). Conclusions: Our experience has suggested the utility of de HIF-1alpha, ACIX, PTEN, p21, thrombocytosis and neutrophilia as prognostic factors in patients with advanced RCC. ACIX has shown to be an independent prognostic factor. No significant financial relationships to disclose.
The relationship between outcome and side effects during imatinib treatment of advanced GIST.
Authors: J. Ahlen, R. Branstrom, J. Zedenius, J. Westerdahl, I. Nilsson
Journal: Journal of Clinical Oncology (2011)

e20524 Background: Imatinib is considered to be the first line therapy in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST). The aim of this study was to analyse the occurrence of moderate to severe or life-threatening side effects and clinical outcome. Methods: 75 consecutive patients (41♂), median age 60 years (range 34-81), with GIST, who had received pre- and/ or postoperative imatinib, were retrospectively reviewed. Metastatic disease was present at initiation of imatinib therapy in 37 cases and 38 patients received (neo)adjuvant imatinib due to high or intermediate risk GISTs based on the modified classification of Fletcher-Mietinen. The primary tumor locations were oesophagus (2), stomach (34), duodenum (7), small intestine (24), colorectal (7) and unclear (1). Twenty patients received treatment for a median of 7 months (range 5 days-23 months) preoperatively. Occurrence of moderate-severe or life-threatening side effects, defined in accordance with Common Terminology Criteria for Adverse Events v4.0 (CTCAE), and clinical outcome were analysed. Results: The median follow up time from diagnosis to the last examination or death was 48 months (range 4-170). In two cases with metastatic GIST, life-threatening consequences from imatinib treatment occurred (tumor perforation and agranulocytosis, respectively). In 27 cases moderate to severe side effects caused temporary or definite interruption of imatinib treatment (7 during down-staging, 17 during adjuvant and 3 during palliative imatinib treatment). In 8 of these, the imatinib treatment was permanently interrupted because of one or more of the following side effects: severe cutaneous reactions (5), gastrointestinal side effects(2), fluid retention (2), myalgia, muscle cramps (2), hearing loss (1) and asthenia (1). The presence of side effects was associated to a favourable recurrence free survival (logrank test; p <0.05) in patients with metastatic GISTs (n=37). No correlation between the occurrence of side effect and outcome was found in the other groups. Conclusions: Our findings indicate that moderate to severe side effects due to imatinib are common and the occurrence of side effects may be associated with a better outcome.
Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center Initiative.
Authors: A. M. Tsimberidou, N. G. Iskander, D. S. Hong, J. J. Wheler, S. Fu, S. A. Piha-Paul, A. Naing, G. S. Falchook, F. Janku, R. Luthra, S. Wen, R. Kurzrock
Journal: Journal of Clinical Oncology (2011)

CRA2500 Background: We initiated a personalized medicine program hypothesizing that tumor molecular analysis and use of targeted therapy to counteract the effects of specific aberrations would improve the outcomes of affected patients. Methods: Molecular analysis was performed in the M. D. Anderson CLIA-certified pathology laboratory. Patients whose tumors had an aberration were treated in the Phase I Program with a matched targeted agent, when available. Results: Tumor molecular analysis was feasible in 852 (89%) of 955 consecutive patients with advanced cancer. Of 852 patients (median, age 56 yrs; prior therapies 4), 354 (41.5%) had ≥ 1 aberration: 10% of patients had a PIK3CA mutation; 19% KRAS; 8% NRAS; 19% BRAF; 3% EGFR; and 2% had a CKIT mutation; 21% had PTEN loss. Results are shown in the table. Median time to treatment failure (TTF) in 161 patients with 1 aberration treated with matched targeted therapy was 5.3 months (95%CI: 4.1, 6.6) vs 3.2 months (95%CI: 2.9 – 4.0) for their prior systemic antitumor therapy (prior to referral to phase I) (p= .0003). For patients with 1 aberration, the CR+PR rate was 29% with matched targeted therapy vs. 8% without matching (p = .0001). The CR+PR rate was 6% in 438 patients without molecular testing treated on the same studies. Conclusions: Preliminary results suggest that in early clinical trials matching patients with targeted drugs based on their molecular profile results in (a) longer TTF compared to their prior therapy and (b) higher rates of response, survival and TTF compared to those seen in patients treated without molecular matching. Support: 3UL1 RR024148 04 S1 and IPCT. [Table: see text]
Nuclease Activity Is Associated with Genomic Instability As Well As Survival in Myeloma; Underlying Mechanisms and Significance
Authors: Masood A Shammas, Leutz Buon, Jianhong Lin, Mehmet K Samur, Jaymin M. Patel, Ankit Vahia, Purushothama Nanjappa, Subodh Kumar, Ahsun Bajwa, Humza Ahmad, David Alagpulinsa, Giovanni Parmigiani, Florence Magrangeas, Stephane Minvielle, Herve Avet-Loiseau, Nikhil C. Munshi
Journal: Blood (2015)
Effectiveness of First and Second Line Nilotinib in Chronic Myeloid Leukemia (CML) Patients with Atypical e1a2 BCR-ABL Transcripts
Authors: Xiaomin Gui, Jinlan Pan, Huiying Qiu, Jiannong Cen, Yongquan Xue, Suning Chen, Jun He, Hongjie Shen, Li Yao, Jun Zhang, Yafang Wu, Wu Depei
Journal: Blood (2014)
Allogeneic Hematopoietic Cell Transplants in Patients with Myelofibrosis Age 60 and Older
Authors: Scott James Samuelson, Brenda M. Sandmaier, Helen E. Heslop, U. Popat, Michael Boyer, Kimberly Hickman, Josef T. Prchal, H. Joachim Deeg
Journal: Blood (2008)
Frequency distribution of SPARC in triple-negative breast cancer patients.
Authors: G. Basu, G. Van Vickle, A. Ghazalpour, R. Ashfaq, Z. Gatalica, R. Blevins, D. Arguello, L. Brisbin, C. Roberts, D. Loesch, R. Bender
Journal: Journal of Clinical Oncology (2011)

37 Background: SPARC (secreted protein acid rich in cysteine) belongs to a group of extracellular matrix proteins and promotes adhesion of cells from the matrix. It plays an important role in tumor development in breast cancer and has a significant bearing on patient prognosis and long term survival. It is also known to predict response to nab-paclitaxel in certain tumor types including breast cancer. In 2005, FDA approved a solvent free formulation of paclitaxel for the treatment of metastatic breast cancer that utilizes albumin bound (nab) technology (nab-paclitaxel). Clinical studies have shown that nab-paclitaxel is significantly more effective than paclitaxel. Our study evaluated the frequency distribution of SPARC among triple negative breast cancer patients in which identification of a novel therapeutic target is warranted. Methods: In a total of 951 breast cancer patients, we analyzed tumor SPARC expression by immunohistochemistry (IHC) using a monoclonal (R&amp;D Systems) and a polyclonal antibody (Exalpha Biologicals). Immunoreactivity was assessed by scoring the percentage of cells stained in each field and by the intensity of staining. A cutoff point of 2+ and &gt;30% stained tumor cells were considered as positive. Results: From our analysis of 951 breast cancer patients profiled, a total of 165 patients (17%) were triple negative for ER, PR and HER2. Within this pathologic subtype, 29% patients stained positive with SPARC monoclonal antibody and 21% stained positive with SPARC polyclonal antibody. The correlation of SPARC tumor staining with hormone receptor status will be presented in detail. Conclusions: We conclude that SPARC over-expression is a functionally important feature of a subset of triple negative breast cancer patients. The triple negative subset of tumors generally has a more aggressive clinical course and does not benefit from conventional targeted therapies. Our study suggests that nab-paclitaxel may serve as a therapeutic agent for the subset of triple negative patients that over-express SPARC. To the best of our knowledge, this is the first study involving a large patient pool in which SPARC has been investigated in a single clinical laboratory using standardized IHC with two different SPARC antibodies.
Magnetic resonance imaging (MRI) as compared to mammogram (MMG) in the evaluation of size, number of lesions, and nodal positivity in breast cancer (BrCa).
Authors: A. Korant, M. Kanaan, S. Sirop, H. Nuthakki, L. Lawrence, R. Hicks, D. Strahle, S. Nagpal, D. Wiese, S. Saha
Journal: Journal of Clinical Oncology (2011)

1102 Background: Direct comparison between MRI and MMG for accuracy of size of the lesion or nodal status in BrCa is lacking. We aim to analyze MMG and MRI findings for nodal status and size of the lesion compared with pathology as a gold standard. Methods: A retrospective analysis was performed on patients (pts) with BrCa who had MRI and MMG. Pts who had excisional biopsy prior to MRI or neoadjuvant therapy were excluded. The number and size of lesions detected by MMG and MRI were compared to pathology. Nodal positivity of pts with additional malignant lesions detected by MRI only was compared to nodal positivity of single lesions detected by MRI and MMG. Results: Between 2003-2010, 318 pts, 414 lesions were identified by MMG and/or MRI. Out of 414 lesions, 210 lesions were detected by MRI and MMG, and size was available to compare to pathology. Out of 210 lesions, MRI overestimated (OE) 56% of lesions by an average of 1.0 cm, MMG underestimated (UE) the same lesions in 53% by an average of 0.6 cm and 9% of lesions MRI and MMG detected same size compared to pathology. Out of 318 pts included in the study 67 pts (21%) had additional lesions detected by MRI which were not detected by MMG; 32 pts (10%) had malignant lesions; 6 pts (2%) had DCIS and 29 pts (9%) had additional benign lesions. The nodal positivity of the 32 pts with MRI detected additional malignant lesions was 50% compared to the remaining 286 pts was 21.5%. Conclusions: MRI effectively evaluates the lesion size with a tendency toward overestimation when compared to MMG. MRI can detect additional lesions when compared to MMG with higher nodal positivity. This finding suggests that MRI-detected lesions are biologically significant and may predict more aggressive disease. Comparison of the lesions detected by MRI and MMG. Comparison of pts with and without additional malignant lesions detected by MRI. Compared to pathology MRI (210 lesions) MMG (210 lesions) P value OE 117 (55.7%) 79 (37.6%) 0.03 UE 77 (36.6%) 111 (52.8%) 0.02 Same size 19 (9%) 20 (9.5%) 0.8 Mean OE (cm) 1.0 0.8 0.8 Mean UE (cm) 0.6 0.6 0.9 Comparison of pts with and without additional malignant lesions detected by MRI. N=318 pts Malignant lesions detected by MRI P value With additional lesions Without additional lesions No. of pts 32 286 <0.0001 Nodal positivity 50% 21.5%
Evaluation of MRD after Administration of Imatinib by Measurement of Real-Time Quantitative PCR-Based Major bcr/abl mRNA.
Authors: Mutsumi Takahata, Satoshi Hashino, Fumie Fujisawa, Takeshi Kondo, Syuichi Ota, Sumiko Kobayashi, Junji Tanaka, Masahiro Imamura, Masahiro Asaka
Journal: Blood (2004)
Evolution of Antithrombin (AT) and Fibrinogen (Fg) Levels during Induction Chemotherapy with L-Asparaginase (Asp) in Adult Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL). Clinical Outcomes and Use of Coagulation Supportive Treatments: The CAPELAL Study.
Authors: Mathilde Hunault-Berger, Yves Gruel, Jean-Luc Harousseau, Martine Delain, Abdallah Maakaroun, Claude-Eric Bulabois, Francis Witz, Marc Bernard, Ingrid Lafon, Jerome Cornillon, Abdel Ladouzi, Alexandra Tizon, Bruno Padrazzi, Zera Tellier, Norbert Ifrah
Journal: Blood (2004)
Enzastaurin in Previously Treated Waldenstrom's Macroglobulinemia: An Open-Label, Multicenter, Phase II Study.
Authors: Irene M Ghobrial, Jean-Luc Harousseau, Steven P Treon, Brianna Harris, Courtney E Lin, Zheng Yuan, Karim Benhadji, James E Wooldridge, Veronique Leblond
Journal: Blood (2009)
The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL)
Authors: Annalisa Chiappella, Patrizia Pregno, Pier Luigi Zinzani, Amalia De Renzo, Andrea Evangelista, Alberto Fabbri, Andres J.M. Ferreri, Silvia Franceschetti, Roberto Freilone, Anna Marina Liberati, Maurizio Martelli, Domenico Novero, Lorella Orsucci, Delia Rota-Scalabrini, Luigi Rigacci, Chiara Rusconi, Giorgina Specchia, Vittorio Stefoni, Alessandra Tucci, Francesco Zaja, Umberto Vitolo
Journal: Blood (2015)
Changes of Cardiac Iron and Function during Pregnancy in Trasfusion-Dependent Thalassemia Patients
Authors: Alessia Pepe, Antonella Meloni, Maria Giovanna Neri, Massimo Allò, Elena Facchini, Tommaso Casini, Aurelio Maggio, Vincenzo Positano, Gianluca Valeri, Elisabetta Chiodi, Cristina Salvatori, Maria Rita Gamberini
Journal: Blood (2015)
Pheochromocytoma (PC)/paraganglioma (PG) and sunitinib: Review of reported cases and literature and case report contribution.
Authors: A. A. Dettino, G. C. Guimaraes, M. Formiga, J. Rinck, A. G. Ribeiro, M. S. Alves, C. Rameri, S. C. Serrano, T. Pagano, M. F. Fanelli
Journal: Journal of Clinical Oncology (2011)

406 Background: Pheochromocytomas/paragangliomas (PC/PG) are rare diseases, but may be responsible for lower quality of life to patients,if progressive or metastatic when malignant. Recently, some benefit has been reported with the use of palliative tyrosine-kinase inhibitors (TKI),such as sunitinib, already approved for kidney cancer. Methods: Review of litearure with a Medline search for PC/PG and suninitib, due to the need to treat a patient with progressive advanced malignant PC, refractory to chemotherapy (CT). Our plan is to contribute reporting safety and efficacy in an additional PC patient. Results: We expose the data found in a table below,with most relevant features related to PC/PG treatments and TKI. Conclusions: Sunitinib as a treatment option to refractory PC/PG may be active and should be further evaluated in this context. A phase II trial is under way (SNIPP; NTC00843037). Other therapies may be evaluated, such as sorafenib, bevacizumab, temozolomide, temsirolimus, thalidomide, and other potential molecular strategies, also with other small molecules, target therapies, and antiangiogenic factors. We plan to follow the reported PC patient and show additional data in the near future. [Table: see text] No significant financial relationships to disclose.
Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide
Authors: Alfred L. Garfall, Eric Lancaster, Edward A Stadtmauer, Simon F. Lacey, Karen Dengel, David E Ambrose, Fang Chen, Minnal Gupta, Irina Kulikovskaya, Dan T. Vogl, Gabriela Plesa, Brendan M Weiss, Regina Ferthio, Celeste Richardson, Jan Joseph Melenhorst, Bruce L Levine, Carl H June, Michael Milone, Adam D. Cohen
Journal: Blood (2016)
Use of total illness burden index for prostate cancer (TIBI-CaP) to predict nonprostate cancer morbidity.
Authors: Michael Andre Liss, Kathryn Osann, Ross Moskowitz, Adam Kaplan, John Billimek, Sheldon Greenfield, Atreya Dash
Journal: Journal of Clinical Oncology (2012)

215 Background: Comorbidities significantly influence how physicians approach the treatment of prostate cancer and should be evaluated prior to the prostate biopsy. The Total Illness Burden Index for Prostate Cancer (TIBI-CaP) patient questionnaire and Charlson Comorbidity Index (CCI) usually calculated by the physician, may provide information on competing risks but have not been compared prospectively. Methods: A prospective observational cohort study was performed of 133 participants prior to obtaining a transrectal ultrasound guided prostate biopsy. Eleven patients had incomplete data or missing follow-up; therefore, a total of 122 (92%) patients were retained for a mean of 21 months (range 4 – 31 months). The TIBI-CaP and CCI scores were compared between subgroups defined by non-elective hospital admission, elective surgery, non-prostate malignancy and survival status using t-tests. Results: Patients averaged 64.5 years at enrollment. One patient died in the study from a metastatic sarcoma. The overall hospital admission rate was 17% (21/122), most commonly from cardiovascular or pulmonary complications. Forty-six men (38%) were diagnosed with cancer on the prostate biopsy. The most common treatments were prostatectomy (39%), active surveillance (26%), or external beam radiation therapy (20%). Twenty-three percent (28/122) had elective surgery and 5% (6/122) were diagnosed with a non-prostate malignancy. Mean TIBI-CaP scores were higher in men who were admitted to the hospital (5.1 vs. 3.5, p=0.03), had elective surgery (4.8 vs. 3.4, p=0.05) or non-prostate cancer (5.5 vs 3.7, p=0.17). No significant differences were observed in CCI scores In stepwise logistic regression, a TIBI-CaP score &gt; 5.0 was associated with 3.5 times higher risk for hospital admission (95% CI: 1.3–10.0, p=0.02). Conclusions: The patient-reported measure of comorbidity (TIBI-CaP) identified patients at high risk for non-elective hospital admission over at 20 month average follow up period and may aid medical decision making specifically in the prostate biopsy population better than that of the Charlson Comorbidity Index.
The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients.
Authors: Giuseppe Visani, Massimo Breccia, Pier Paolo Piccaluga, Antonella Gozzini, Giorgina Specchia, Enrico Montefusco, Enrica Morra, Mario Annunziata, Luigiana Luciano, Andrea Camera, Francesco Cavazzini, Fabio Stagno, Francesco Di Raimondo, Patrizia Pregno, Francesca Pirillo, Valeria Santini, Alberto Bosi, Matteo Pacilli, Ester Pungolino, Emilio Usala, Emanuele Angelucci, Monica Crugnola, Gianni Binotto, Elena Maino, Federica Loscocco, Sara Barulli, Giuseppina Nicolini, Antonio Cuneo, Roberto Latagliata, Felicetto Ferrara, Alessandro Isidori
Journal: Blood (2009)
Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).
Authors: Robin A. Roberts, Lisa M. Rimsza, Louis Staudt, Andreas Rosenwald, Wing-Chung Chan, Sandeep Dave, Randy D. Gascoyne, Joseph M. Connors, Erlend B. Smeland, H.K. Muller-Hermelink, Elias Campo, Elaine S. Jaffe, Wyndham Wilson, Bruce K. Tan, Richard I. Fisher, Thomas M. Grogan, Thomas P. Miller
Journal: Blood (2006)
Prospective Analysis of the Quality of Life of Chronic Phase CML Patients on Second Generation Tyrosine Kinase Inhibitors after Imatinib Failure. an Observational Study
Authors: Franck E. Nicolini, Nicolas Vantard, Stephane Giraudier, Mael Heiblig, Hyacinthe Johnson-Ansah, Lydia Roy, Claude-Eric Bulabois, Denis Caillot, Martine Escoffre-Barbe, Eric Jourdan, Pascale Cony-Makhoul, Agnes Guerci-Bresler, Laurence Legros, Laurent Sutton, Martine Gardembas, Emmanuel Gyan, Annelore Le Maux, Carine Guinard-Azadian, Hesham Mohamed, Mohamad Sobh, Helene Labussiere-Wallet, Gabriel Etienne
Journal: Blood (2014)
Prognostic Importance of Duration of MDS Prior to Randomization Between Decitabine (DAC) Vs. Best Supportive Care (BSC) In Elderly IPSS Intermediate-2 and High Risk MDS Patients: Results of the 06011 EORTC-GMDSSG Phase III Trial
Authors: Michael Lubbert, Stefan Suciu, Uwe Platzbecker, Aristoteles A.N. Giagounidis, Dominik Selleslag, Boris Labar, Ulrich Germing, Andrea Kuendgen, Helmut R. Salih, Petra Muus, Björn Rüter, Arnold Ganser, Carlo Aul, Theo de Witte, Pierre W. Wijermans
Journal: Blood (2010)
Clinical outcome of extragonadal germ cell tumors: Retrospective analysis at a single institution in Japan.
Authors: Ken-Ichi Kakimoto, Ken Takeda, Wataru Nakata, Masashi Nakayama, Yasuyuki Arai, Kazuo Nishimura
Journal: Journal of Clinical Oncology (2012)

345 Background: Extragonadal germ cell tumors (EGGCT) are very rare and account for only 2% to 5% of all malignant germ cell neoplasms. Although multimodality treatment, including cisplatin-based chemotherapy and postchemotherapy surgery, has improved the prognosis of patients with EGGCT, few findings are available for these tumors. We therefore performed a retrospective analysis of Japanese patients with EGGCT. Methods: We performed a retrospective review of the medical records of 34 male patients ranging in age from 18 to 62 years (median age, 30 years) treated at our institution between 1982 and 2010. Fifteen patients (44%) had primary mediastinal EGGCT, 16 patients (47%) had primary retroperitoneal EGGCT, and three patients (9%) had primary mediastinal and retroperitoneal EGGCT. Results: Twenty-six patients (76%) had nonseminomatous EGGCT, and eight patients (24%) had seminomatous histology. Surgical procedures were performed in five patients (15%) as induction treatment. Three of them had seminomatous histology and were continuously disease-free after adjuvant chemotherapy. Twenty-nine patients (85%) had received cisplatin-containing regimen as induction therapy. Twenty-three patients underwent post–chemotherapy surgery, and 14 of them (60%) had residual viable malignant cells. On univariate analysis, nonseminomatous EGGCT (P&lt;0.01) and resistance to cisplatin (lack of achievement of CR/PRm- by induction chemotherapy; P&lt;0.01) were identified as negative prognostic factors for survival. Twenty of 34 patients (59%) were alive without disease, and 13 patients with nonseminomatous histology died of disease progression. The overall 10-year survival rate for all patients was 53%. Conclusions: Patients with seminomatous EGGCT have a very good prognosis, while nonseminomatous histology and resistance to cisplatin were found to be negative prognostic factors.